BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is now covered by analysts at
Weiss Ratings. They set a "sell (d+)" rating on the stock.
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was upgraded by analysts at Raymond James Financial, Inc. to a "moderate buy" rating.
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference